Authors

Robert A. Copeland | PH.D.

Scientist, Author, Entrepreneur

Mission

To relieve human suffering by the discovery and development of novel medicines to treat diseases
of significant unmet need.

Biographical Paragraph

Robert A. Copeland, Ph.D. founded Accent Therapeutics, Inc. in September 2017
and serves as its President and Chief Scientific Officer. He is also President of the
independent consulting firm, Ki Consultant, LLC. He was formerly President of
Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice
President of Cancer Biology, Oncology Center of Excellence in Drug Discovery,
GlaxoSmithKline. Dr. Copeland serves on a number of advisory boards within
industry, academia, professional societies and professional journals. He received
his B.S. in chemistry from Seton Hall University, his doctorate in chemistry from
Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow
at the California Institute of Technology. His research interest is in elucidating the
determinants of drug recognition by their biological targets and the use of this
information in the discovery and design of new medicines. He has contributed to
drug discovery and development efforts leading to 19 investigational new drugs
entering human clinical trials. These include the cancer drugs Tazverik™
(tazemetostat), Tafinlar™ (dabrafenib) and Mekinist™ (trametinib), the anemia
drug Duvroq™ (daprodustat) and the antibiotic Altabax™ (retapamulin). Dr.
Copeland has contributed more than 200 publications to the scientific literature,
holds 14 issued U.S. patents and has authored 5 books in the areas of protein
science and enzymology. In 2016 he was elected a Fellow of the American
Association for the Advancement of Science (AAAS) and in 2020 he was elected a
Fellow of the Royal Society of Chemistry.

Related Articles

Back to top button

Important This site makes use of cookies which may contain tracking information about visitors. By continuing to browse this site you agree to our use of cookies.